Replimune Group (REPL) Revenue & Revenue Breakdown
Replimune Group Revenue Highlights
Replimune Group Revenue by Period
Replimune Group Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-03-31 | - | - |
Replimune Group generated - in revenue during NA 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Replimune Group Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | -100.00% |
| 2024-03-31 | $4.04M | 100.00% |
| 2023-12-31 | - | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | 100.00% |
| 2021-12-31 | - | 100.00% |
| 2021-09-30 | - | 100.00% |
| 2021-06-30 | - | 100.00% |
| 2021-03-31 | - | 100.00% |
| 2020-12-31 | - | 100.00% |
| 2020-09-30 | - | 100.00% |
| 2020-06-30 | - | 100.00% |
| 2020-03-31 | - | 100.00% |
| 2019-12-31 | - | 100.00% |
| 2019-09-30 | - | 100.00% |
| 2019-06-30 | - | 100.00% |
| 2019-03-31 | - | 100.00% |
| 2018-12-31 | - | 100.00% |
| 2018-09-30 | - | 100.00% |
| 2018-06-30 | - | 100.00% |
| 2018-03-31 | - | 100.00% |
| 2017-12-31 | - | 100.00% |
| 2017-09-30 | - | 100.00% |
| 2017-06-30 | - | 100.00% |
| 2017-03-31 | - | - |
Replimune Group generated - in revenue during Q1 2025, up -100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Replimune Group Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| UTHR | United Therapeutics | $2.33B | $714.90M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| PTGX | Protagonist Therapeutics | $60.00M | $4.17M |
| MRUS | Merus | $43.95M | $7.33M |
| NAMS | NewAmsterdam Pharma Company | $14.09M | $1.40M |
| KRON | Kronos Bio | $6.29M | $2.69M |
| CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
| PRTC | PureTech Health | $3.33M | $178.57K |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| KROS | Keros Therapeutics | $151.00K | $83.00K |
| NUVL | Nuvalent | - | - |
| GOSS | Gossamer Bio | - | $95.84M |
| AVTE | Aerovate Therapeutics | - | - |
| CERE | Cerevel Therapeutics | - | - |
| REPL | Replimune Group | - | - |
| KURA | Kura Oncology | - | - |
| SNDX | Syndax Pharmaceuticals | - | $3.50M |
| VTYX | Ventyx Biosciences | - | - |
| MLYS | Mineralys Therapeutics | - | - |
| NVCT | Nuvectis Pharma | - | - |
REPL Revenue FAQ
What is Replimune Group’s yearly revenue?
Replimune Group's yearly revenue for 2024 was $0, representing an increase of 100.00% compared to 2023. The company's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. REPL's yearly revenue for 2022 was $0, representing an increase of 100.00% compared to 2021.
What is Replimune Group’s quarterly revenue?
Replimune Group's quarterly revenue for Q1 2025 was $0, a -100.00% decrease from the previous quarter (Q4 2024), and a 0% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $4.04M, a 100.00% increase from the previous quarter (Q3 2024), and a 0% increase year-over-year (Q4 2023). REPL's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a 0% increase year-over-year (Q3 2023).
What is Replimune Group’s revenue growth rate?
Replimune Group's revenue growth rate for the last 3 years (2022-2024) was 0%, and for the last 5 years (2020-2024) was 0%.